The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization.

Source:http://linkedlifedata.com/resource/pubmed/id/16775841

Download in:

View as

General Info

PMID
16775841